NRx Pharmaceuticals (NRXP) Issues Shareholder Update Letter

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) today announced that the Company posted a new Shareholder Update Letter on its website NRx Shareholder Update and further invites interested parties to subscribe to their email alert service to stay up to date on company's progress here: NRx Email Alerts . (Note: not all updates will be included in a Press Release in the future).

Today's update highlights potential implications of the Company's recent activities at the annual meeting of the American Society of Clinical Psychopharmacology. The key points include:

• Intravenous and intranasal ketamine were highlighted as emerging standards of care for severe depression and suicidality
• Planned NDA filing for NRX-100, our preservative free IV ketamine, for Suicidal Depression in 2024, is based on well controlled trials against both placebo and active comparator. Fast Track Designation was previously granted
• An independent FDA advisory panel recently voted against MDMA, a potent, class I psychedelic, refocusing attention on already-approved Schedule 3 drugs such as ketamine for treatment of suicidal depression. The FDA panel and emerging guidance highlights the complexity of clinical trials of DEA Schedule 1 hallucinogens that do not have already-approved human uses
• NRx anticipates that an important issue for longer term use of ketamine in depression will be the current multidose vial presentation that contains potentially toxic preservatives previously acceptable for one time use but less suitable for repeated use. NRX-100 is planned as a single-dose, preservative-free medication.

Please subscribe to the Company's email for future updates. NRX Email Alerts Not all of these will be the subject of a Press Release in the future.

You May Also Be Interested In

• ARS Pharmaceuticals names Donn Casale as CEO, replacing co-founder
• Nasdaq to delist Platinum Analytics by July 16 unless appeal filed
• James D. Burnham leaves RenX board, hired as director of growth & M&A